| 查看: 359 | 回复: 0 | |||
[交流]
One-Compound-Multi-Target: Combination Prospect of Natural Compounds
|
|
Tissue plasminogen activator (t-PA) is the only FDA-approved drug for acute ischemic stroke treatment, but its clinical use is limited due to the narrow therapeutic time window and severe adverse effects, including hemorrhagic transformation (HT) and neurotoxicity. One of the potential resolutions is to use adjunct therapies to reduce the side effects and extend t-PA's therapeutic time window. However, therapies modulating single target seem not to be satisfied, and a multitarget strategy is warranted to resolve such complex disease. Recently, large amount of efforts have been made to explore the active compounds from herbal supplements to treat ischemic stroke. Some natural compounds revealed both neuro- and bloodbrain- barrier (BBB)-protective effects by concurrently targeting multiple cellular signaling pathways in cerebral ischemia-reperfusion injury. Thus, those compounds are potential to be one-drug-multi-target agents as combined therapy with t-PA for ischemic stroke.? In this review article, we summarize current progress about molecular targets involving in t-PA-mediated HT and neurotoxicity in ischemic brain injury. Based on these targets, we select 23 promising compounds from currently available literature with the bioactivities simultaneously targeting several important molecular targets. We propose that those compounds merit further investigation as combined therapy with t-PA. Finally, we discuss the potential drawbacks of the natural compounds' studies and raise several important issues to be addressed in the future for the development of natural compound as an adjunct therapy. 发自小木虫IOS客户端 |
回复此楼» 猜你喜欢
🔥速览｜AACR 2026 mRNA肿瘤疫苗临床捷报
已经有0人回复
-
深圳理工大学和东南大学联合培养博士招生（2026年9月入学）
已经有11人回复
-
药理学论文润色/翻译怎么收费?
已经有173人回复
-
211高校2026年入学博士名额
已经有13人回复
-
211高校2026年入学博士名额
已经有9人回复
-
211高校2026年入学博士名额
已经有3人回复